Harnessing the immune system through programmed death-1 blockade in the management of Hodgkin lymphoma.

IF 3.9 Q2 ONCOLOGY

Blood and Lymphatic Cancer-Targets and Therapy Pub Date : 2017-02-16 eCollection Date: 2017-01-01 DOI:10.2147/BLCTT.S110665

Melody B Oncale, Hossein Maymani, Loretta J Nastoupil

{"title":"Harnessing the immune system through programmed death-1 blockade in the management of Hodgkin lymphoma.","authors":"Melody B Oncale, Hossein Maymani, Loretta J Nastoupil","doi":"10.2147/BLCTT.S110665","DOIUrl":null,"url":null,"abstract":"<p><p>Immunotherapy is a rapidly evolving therapeutic option in the treatment of lymphoma. Neoplastic cells evade immune recognition through the programmed death (PD)-1/PD-ligand immune checkpoint pathway. Several novel agents have been developed to restore the immune system's ability to recognize and destroy cancer cells. Nivolumab and pembrolizumab are two anti-PD-1 antibodies that have demonstrated success in the treatment of refractory Hodgkin lymphoma. Harnessing the immune system's ability to target neoplastic cells, ideally without the use of cytotoxic chemotherapeutic agents, is one way in which these novel agents are changing the therapeutic landscape in the treatment of lymphomas. Here, we review the emerging data regarding checkpoint inhibitors in the management of Hodgkin lymphoma, the unique adverse effects encountered with the use of these agents, and a practical approach to the management of these adverse effects. Additionally, we discuss upcoming trials that will further assess the promising future developments of checkpoint inhibition in the treatment of not only Hodgkin lymphoma but also other B cell lymphomas and myeloma. These agents offer immense promise of a future where many lymphomas can be treated without the toxic effects of chemotherapeutic agents.</p>","PeriodicalId":42368,"journal":{"name":"Blood and Lymphatic Cancer-Targets and Therapy","volume":null,"pages":null},"PeriodicalIF":3.9000,"publicationDate":"2017-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/70/6e/blctt-7-001.PMC6467338.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood and Lymphatic Cancer-Targets and Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/BLCTT.S110665","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2017/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Immunotherapy is a rapidly evolving therapeutic option in the treatment of lymphoma. Neoplastic cells evade immune recognition through the programmed death (PD)-1/PD-ligand immune checkpoint pathway. Several novel agents have been developed to restore the immune system's ability to recognize and destroy cancer cells. Nivolumab and pembrolizumab are two anti-PD-1 antibodies that have demonstrated success in the treatment of refractory Hodgkin lymphoma. Harnessing the immune system's ability to target neoplastic cells, ideally without the use of cytotoxic chemotherapeutic agents, is one way in which these novel agents are changing the therapeutic landscape in the treatment of lymphomas. Here, we review the emerging data regarding checkpoint inhibitors in the management of Hodgkin lymphoma, the unique adverse effects encountered with the use of these agents, and a practical approach to the management of these adverse effects. Additionally, we discuss upcoming trials that will further assess the promising future developments of checkpoint inhibition in the treatment of not only Hodgkin lymphoma but also other B cell lymphomas and myeloma. These agents offer immense promise of a future where many lymphomas can be treated without the toxic effects of chemotherapeutic agents.

查看原文本刊更多论文

霍奇金淋巴瘤治疗中通过程序性死亡1阻断控制免疫系统。

免疫疗法是治疗淋巴瘤的一种快速发展的治疗选择。新生细胞通过程序性死亡（PD）-1/PD配体免疫检查点途径逃避免疫识别。已经开发了几种新的试剂来恢复免疫系统识别和破坏癌症细胞的能力。尼沃单抗和pembrolizumab是两种抗PD-1抗体，已证明在治疗难治性霍奇金淋巴瘤方面取得了成功。利用免疫系统靶向肿瘤细胞的能力，理想情况下不使用细胞毒性化疗药物，是这些新药物改变淋巴瘤治疗格局的一种方式。在这里，我们回顾了关于检查点抑制剂在霍奇金淋巴瘤治疗中的新数据，使用这些药物时遇到的独特不良反应，以及管理这些不良反应的实用方法。此外，我们还讨论了即将进行的试验，这些试验将进一步评估检查点抑制在治疗霍奇金淋巴瘤以及其他B细胞淋巴瘤和骨髓瘤方面的前景。这些药物为许多淋巴瘤的治疗提供了巨大的前景，而不会产生化疗药物的毒性作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Blood and Lymphatic Cancer-Targets and Therapy ONCOLOGY-

自引率

7.10%

发文量

审稿时长

16 weeks

期刊介绍： Blood and Lymphatic Cancer: Targets and Therapy is an international, peer reviewed, open access journal focusing on blood and lymphatic cancer research, identification of therapeutic targets, and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival, and quality of life for the cancer patient. Specific topics covered in the journal include: Epidemiology, detection and screening Cellular research and biomarkers Identification of biotargets and agents with novel mechanisms of action Optimal clinical use of existing anticancer agents, including combination therapies Radiation, surgery, bone marrow transplantation Palliative care Patient adherence, quality of life, satisfaction Health economic evaluations.